ArticleCancers2022

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma.

Alexander Schulz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.